Skip to main content
Log in

Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR)

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Polymyalgia rheumatica (PMR) is a common inflammatory disease of the elderly in western countries, but the prevalence is apparently different between races and countries. Until now, an epidemiologic study of PMR is limited in Korea. We retrospectively evaluated the clinical data of 78 patients with PMR who were treated in 5 tertiary hospitals, and analyzed initial laboratory data, symptoms, therapeutic responses, and prognostic factors for relapse 1 year after treatments. Sixty percent of patients had pain in both shoulder and hip girdles with 10.6 weeks of duration, 75.9 ± 32.7 mm/h of erythrocyte sedimentation rate (ESR), and 6.2 ± 6.4 mg/dl of C-reactive protein. The rate of relapse and remission at 1 year was 38.4 and 2.5 %, respectively. The rate of overall relapse was 46.1 %, and the relapse occurred mostly in a year, especially between 6 and 12 months after diagnosis. There were more female in relapse group (88.9 %, p = 0.037), and cumulative steroid dose of 1 year was significantly higher in relapse group (5.5 ± 2.7 vs. 4.4 ± 2.5 g, p = 0.018). Independent risk factors for relapse were initial CRP ≥ 2.5 mg/dl (OR 6.296, p = 0.047) and the use of hydroxychloroquine (OR 6.798, p = 0.035). Initial dosage or tapering speed of steroid did not influence on prognosis. In Korean patients with PMR, baseline clinical characteristics and relapse rate were similar to previous studies, but our patients accompanied no giant cell arteritis and showed lower remission rate as well as delayed therapeutic response and later occurrence of relapse. More aggressive management would be needed according to the clinical status of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Salvarani C, Cantini F, Boiardi L, Hunder GG (2002) Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 347:261–271

    Article  Google Scholar 

  2. Gonzalez-Gay MA, Agudo M, Martinez-Dubois C, Pompei O, Blanco R (2010) Medical management of polymyalgia rheumatica. Expert Opin Pharmacother 11:1077–1087

    Article  CAS  Google Scholar 

  3. Leeb BF, Bird HA (2004) A disease activity score for polymyalgia rheumatica. Ann Rheum Dis 63:1279–1283

    Article  CAS  Google Scholar 

  4. Lawrence RC, Felson DT, Helmick CG et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 58:26–35

    Article  Google Scholar 

  5. Dasgupta B, Salvarani C, Schirmer M et al (2008) Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. J Rheumatol 35:270–277

    PubMed  Google Scholar 

  6. Bird HA, Leeb BF, Montecucco CM et al (2005) A comparison of the sensitivity of diagnostic criteria for polymyalgia rheumatica. Ann Rheum Dis 64:626–629

    Article  CAS  Google Scholar 

  7. Dasgupta B, Matteson EL, Maradit-Kremers H (2007) Management guidelines and outcome measures in polymyalgia rheumatica (PMR). Clin Exp Rheumatol 25:130–136

    CAS  PubMed  Google Scholar 

  8. Dasgupta B, Borg FA, Hassan N et al (2010) BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 49:186–190

    Article  Google Scholar 

  9. Salvarani C, Cantini F, Macchioni P et al (1998) Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 41:1221–1226

    Article  CAS  Google Scholar 

  10. Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, Olivieri I, Hunder GG (2000) The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J Rheumatol 27:2179–2184

    CAS  PubMed  Google Scholar 

  11. Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE (2005) Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol 32:65–73

    PubMed  Google Scholar 

  12. Smith CA, Fidler WJ, Pinals RS (1983) The epidemiology of giant cell arteritis. Report of a ten-year study in Shelby County Tennessee. Arthritis Rheum 26:1214–1219

    Article  CAS  Google Scholar 

  13. Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH (1979) An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 38:434–439

    Article  CAS  Google Scholar 

  14. Wilke WS, Wysenbeek AJ, Krall PL, Segal AM (1985) Masked presentation of giant-cell arteritis. Cleve Clin Q 52:155–159

    Article  CAS  Google Scholar 

  15. Myklebust G, Gran JT (1996) A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br J Rheumatol 35:1161–1168

    Article  CAS  Google Scholar 

  16. Salvarani C, Cantini F, Niccoli L et al (2005) Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 53:33–38

    Article  Google Scholar 

  17. Kyle V, Hazleman BL (1993) The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 52:847–850

    Article  CAS  Google Scholar 

  18. Hutchings A, Hollywood J, Lamping DL et al (2007) Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum 57:803–809

    Article  Google Scholar 

  19. Mackie SL, Hensor EM, Haugeberg G, Bhakta B, Pease CT (2010) Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study. Rheumatology (Oxford) 49:716–722

    Article  Google Scholar 

  20. Ornetti P, Guillibert-Karras C, Garrot JF et al (2011) Study of professional practices among rheumatologists in Burgundy: initial corticotherapy in polymyalgia rheumatica. Clin Rheumatol 30:51–56

    Article  Google Scholar 

  21. Hernandez-Rodriguez J, Cid MC, Lopez-Soto A, Espigol-Frigole G, Bosch X (2009) Treatment of polymyalgia rheumatica: a systematic review. Arch Intern Med 169:1839–1850

    Article  CAS  Google Scholar 

  22. Cimmino MA, Parodi M, Caporali R, Montecucco C (2006) Is the course of steroid-treated polymyalgia rheumatica more severe in women? Ann N Y Acad Sci 1069:315–321

    Article  CAS  Google Scholar 

  23. Cantini F, Salvarani C, Olivieri I et al (2000) Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 30:17–24

    Article  CAS  Google Scholar 

  24. Caporali R, Cimmino MA, Ferraccioli G et al (2004) Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 141:493–500

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by Konkuk University in 2012.

Conflict of interest

The authors have no conflicts of interest of any kind to declare in the materials or services referred to in this article.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hae-Rim Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, J.H., Choi, S.T., Kim, J.S. et al. Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR). Rheumatol Int 33, 1475–1480 (2013). https://doi.org/10.1007/s00296-012-2580-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-012-2580-4

Keywords

Navigation